Disease Progression, Resilience, and Inflammation Markers During the Coronavirus Disease 2019 Pandemic in Parkinson's Disease

Claire Pauly; Enrico Glaab; Maxime Hansen; Camille Martin-Gallausiaux; Mirko Ledda; Tainá M. Marques; Paul Wilmes; Rejko Krüger; Nico J. Diederich; the NCER-PD Consortium

doi:10.1002/mds.29212

Disease Progression, Resilience, and Inflammation Markers During the Coronavirus Disease 2019 Pandemic in Parkinson's Disease

Claire Pauly^*
, Enrico Glaab
, Maxime Hansen
, Camille Martin-Gallausiaux
, Mirko Ledda
, Tainá M. Marques
, Paul Wilmes
, Rejko Krüger
, Nico J. Diederich
, the NCER-PD Consortium

^*Corresponding author for this work

Transversal Translational Medicine

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	2315-2317
Number of pages	3
Journal	Movement Disorders
Volume	37
Issue number	11
Early online date	23 Sept 2022
DOIs	https://doi.org/10.1002/mds.29212
Publication status	Published - Nov 2022

Access to Document

10.1002/mds.29212Licence: CC BY

Cite this

@article{e8a9308c58704149bb189515917b3dc6,

title = "Disease Progression, Resilience, and Inflammation Markers During the Coronavirus Disease 2019 Pandemic in Parkinson's Disease",

author = "Claire Pauly and Enrico Glaab and Maxime Hansen and Camille Martin-Gallausiaux and Mirko Ledda and Marques, \{Tain{\'a} M.\} and Paul Wilmes and Rejko Kr{\"u}ger and Diederich, \{Nico J.\} and \{the NCER-PD Consortium\}",

note = "Funding Information: This work was supported by the Luxembourg National Research Fund (FNR) within the National Centre for Excellence in Research on Parkinson's disease (FNR/NCER13/BM/11264123) and within the PEARL Excellence Program (FNR/P13/6682797) to R.K. E.G. received funding support from the Fonds National de la Recherche Luxembourg as part of the COVID‐19 Fast‐Track research project CovScreen (COVID‐19/2020‐1/14715687) and from the European Union's Horizon 2020 research and innovation program under grant ERAPERMED 2020–314 for the project DIGI‐PD. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant 863664). Data used in the preparation of this manuscript were obtained from the National Centre of Excellence in Research on Parkinson's Disease (NCER‐PD). We would like to thank all participants of the Luxembourg Parkinson's Study for their important support on our research. Furthermore, we acknowledge the joint effort of the NCER‐PD Consortium members from the partner institutions Luxembourg Centre for Systems Biomedicine, Luxembourg Institute of Health, Centre Hospitalier de Luxembourg and Laboratoire National de Sant{\'e} generally contributing to the Luxembourg Parkinson's Study as listed here: Geeta Acharya (6), Gloria Aguayo (6), Myriam Alexandre (6), Muhammad Ali (1), Wim Ammerlann (6), Rudi Balling (1), Michele Bassis (1), Katy Beaumont (6), Regina Becker (1), Camille Bellora (6), Guy Berchem (5), Daniela Berg (15), Alexandre Bisdorff (8), Kathrin Brockmann (15), Jessica Calmes (6), Lorieza Castillo (6), Gessica Contesotto (6), Rene Dondelinger (8), Daniela Esteves (6), Guy Fagherazzi (6), Jean‐Yves Ferrand (6), Manon Gantenbein (6), Thomas Gasser (15), Piotr Gawron (1), Soumyabrata Ghosch (1), Marijus Giraitis (2,5), Clarissa Gomes (1), Elisa Gomes de Lope (1), J{\'e}r{\^o}me Graas (6), Mariela Graziano (21), Valentin Groues (1), Anne Gr{\"u}newald (1), Wei Gu (1), Ga{\"e}l Hammot (6), Anne‐Marie Hanff (2), Linda Hansen (1,3), Michael Heneka (1), Estelle Henry (6), Sylvia Herbrink (9), Sascha Herzinger (1), Michael Heymann (6), Michele Hu (11), Alexander Hundt (6), Nadine Jacoby (22), Jacek Jaroslaw Lebioda (1), Yohan Jaroz (1), Quentin Klopfenstein (1), Jochen Klucken (2,5), Pauline Lambert (2), Zied Landoulsi (1), Roseline Lentz (10), Inga Liepelt (15), Robert Liszka (18), Laura Longhino (5), Victoria Lorentz (6), Paula Cristina Lupu (6), Clare Mackay (18), Walter Maetzler (19), Katrin Marcus (17), Guilherme Marques (6), Patricia Martins Conde (1), Patrick May (1), Deborah Mcintyre (2), Chouaib Mediouni (6), Francoise Meisch (1), Myriam Menster (6), Maura Minelli (6), Michel Mittelbronn (1,7), Brit Mollenhauer (16), Carlos Moreno (1), Friedrich M{\"u}hlschlegel (7), Romain Nati (5), Ulf Nehrbass (6), Sarah Nickels (1), Beatrice Nicolai (5), Jean‐Paul Nicolay (23), Jean‐Paul Nicolay (23), Fozia Noor (6), Marek Ostaszewski (1), Sinthuja Pachchek (1), Laure Pauly (1), Lukas Pavelka (1,2,5), Magali Perquin (6), Rosalina Ramos Lima (6), Armin Rauschenberger (1), Rajesh Rawal, Dheeraj Reddy Bobbili (1), Eduardo Rosales (6), Isabel Rosety (6), Kirsten Roomp (1), Estelle Sandt (6), Stefano Sapienza (1), Venkata Satagopam (1), Margaux Schmitt (6), Sabine Schmitz (1), Reinhard Schneider (1), Jens Schwamborn (1), Jean‐Edouard Schweitzer (1), Amir Sharify (6), Ekaterina Soboleva (1,2,5), Kate Sokolowska (6), Olivier Terwindt (1,2,5), Hermann Thien (6), Elodie Thiry (5), Rebecca Ting Jiin Loo (1), Christophe Trefois (1), Johanna Trouet (6), Olena Tsurkalenko (3), Michel Vaillant (6), Mesele Valenti (6), Liliana Vilas Boas (5), Maharshi Vyas (1), Richard Wade‐Martins (13), Evi Wollscheid‐Lengeling (1), Gelani Zelimkhanov (5). We thank Prof. Jochen Klucken for valuable feedback. (1) Luxembourg Centre for Systems Biomedicine, University of Luxembourg. (6) Luxembourg Institute of Health, Strassen, Luxembourg. (5) Centre Hospitalier de Luxembourg, Strassen. Luxembourg. (7) Laboratoire National de Sant{\'e}, Dudelange, Luxembourg. (8) Centre Hospitalier Emile Mayrisch, Esch‐sur‐Alzette, Luxembourg. (9) Centre Hospitalier du Nord, Ettelbr{\"u}ck, Luxembourg. (10) Parkinson Luxembourg Association, Leudelange, Luxembourg. (11) Oxford Parkinson's Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. (12) Oxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK. (13) Oxford Centre for Human Brain Activity, Welcome Centre for Integrative Neuroimaging, Department of Psychiatry, University of Oxford, Oxford. (14) Centre of Neurology and Hertie Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, University Hospital of T{\"u}bingen, T{\"u}bingen, Germany. (15) Paracelsus‐Elena Klinik, Kassel, Germany. (16) Ruhr University of Bochum, Bochum, Germany. (17) Westpfalz‐ Klinikum GmbH, Kaiserlautern, Germany. (18) Department of Neurology, University Medical Centre Schleswig‐Holstein, Kiel, Germany. (19) Department of Neurology Philipps, University of Marburg, Marburg, Germany. (20) Association of Physiotherapists in Parkinson's Disease Europe, Esch‐sur‐Alzette, Luxembourg. (21) Private Practice Ettelbruck, Luxembourg. (22) Private Practice, Luxembourg, Luxembourg. ",

year = "2022",

month = nov,

doi = "10.1002/mds.29212",

language = "English",

volume = "37",

pages = "2315--2317",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley \& Sons Inc.",

number = "11",

}

TY - JOUR

T1 - Disease Progression, Resilience, and Inflammation Markers During the Coronavirus Disease 2019 Pandemic in Parkinson's Disease

AU - Pauly, Claire

AU - Glaab, Enrico

AU - Hansen, Maxime

AU - Martin-Gallausiaux, Camille

AU - Ledda, Mirko

AU - Marques, Tainá M.

AU - Wilmes, Paul

AU - Krüger, Rejko

AU - Diederich, Nico J.

AU - the NCER-PD Consortium

N1 - Funding Information: This work was supported by the Luxembourg National Research Fund (FNR) within the National Centre for Excellence in Research on Parkinson's disease (FNR/NCER13/BM/11264123) and within the PEARL Excellence Program (FNR/P13/6682797) to R.K. E.G. received funding support from the Fonds National de la Recherche Luxembourg as part of the COVID‐19 Fast‐Track research project CovScreen (COVID‐19/2020‐1/14715687) and from the European Union's Horizon 2020 research and innovation program under grant ERAPERMED 2020–314 for the project DIGI‐PD. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant 863664). Data used in the preparation of this manuscript were obtained from the National Centre of Excellence in Research on Parkinson's Disease (NCER‐PD). We would like to thank all participants of the Luxembourg Parkinson's Study for their important support on our research. Furthermore, we acknowledge the joint effort of the NCER‐PD Consortium members from the partner institutions Luxembourg Centre for Systems Biomedicine, Luxembourg Institute of Health, Centre Hospitalier de Luxembourg and Laboratoire National de Santé generally contributing to the Luxembourg Parkinson's Study as listed here: Geeta Acharya (6), Gloria Aguayo (6), Myriam Alexandre (6), Muhammad Ali (1), Wim Ammerlann (6), Rudi Balling (1), Michele Bassis (1), Katy Beaumont (6), Regina Becker (1), Camille Bellora (6), Guy Berchem (5), Daniela Berg (15), Alexandre Bisdorff (8), Kathrin Brockmann (15), Jessica Calmes (6), Lorieza Castillo (6), Gessica Contesotto (6), Rene Dondelinger (8), Daniela Esteves (6), Guy Fagherazzi (6), Jean‐Yves Ferrand (6), Manon Gantenbein (6), Thomas Gasser (15), Piotr Gawron (1), Soumyabrata Ghosch (1), Marijus Giraitis (2,5), Clarissa Gomes (1), Elisa Gomes de Lope (1), Jérôme Graas (6), Mariela Graziano (21), Valentin Groues (1), Anne Grünewald (1), Wei Gu (1), Gaël Hammot (6), Anne‐Marie Hanff (2), Linda Hansen (1,3), Michael Heneka (1), Estelle Henry (6), Sylvia Herbrink (9), Sascha Herzinger (1), Michael Heymann (6), Michele Hu (11), Alexander Hundt (6), Nadine Jacoby (22), Jacek Jaroslaw Lebioda (1), Yohan Jaroz (1), Quentin Klopfenstein (1), Jochen Klucken (2,5), Pauline Lambert (2), Zied Landoulsi (1), Roseline Lentz (10), Inga Liepelt (15), Robert Liszka (18), Laura Longhino (5), Victoria Lorentz (6), Paula Cristina Lupu (6), Clare Mackay (18), Walter Maetzler (19), Katrin Marcus (17), Guilherme Marques (6), Patricia Martins Conde (1), Patrick May (1), Deborah Mcintyre (2), Chouaib Mediouni (6), Francoise Meisch (1), Myriam Menster (6), Maura Minelli (6), Michel Mittelbronn (1,7), Brit Mollenhauer (16), Carlos Moreno (1), Friedrich Mühlschlegel (7), Romain Nati (5), Ulf Nehrbass (6), Sarah Nickels (1), Beatrice Nicolai (5), Jean‐Paul Nicolay (23), Jean‐Paul Nicolay (23), Fozia Noor (6), Marek Ostaszewski (1), Sinthuja Pachchek (1), Laure Pauly (1), Lukas Pavelka (1,2,5), Magali Perquin (6), Rosalina Ramos Lima (6), Armin Rauschenberger (1), Rajesh Rawal, Dheeraj Reddy Bobbili (1), Eduardo Rosales (6), Isabel Rosety (6), Kirsten Roomp (1), Estelle Sandt (6), Stefano Sapienza (1), Venkata Satagopam (1), Margaux Schmitt (6), Sabine Schmitz (1), Reinhard Schneider (1), Jens Schwamborn (1), Jean‐Edouard Schweitzer (1), Amir Sharify (6), Ekaterina Soboleva (1,2,5), Kate Sokolowska (6), Olivier Terwindt (1,2,5), Hermann Thien (6), Elodie Thiry (5), Rebecca Ting Jiin Loo (1), Christophe Trefois (1), Johanna Trouet (6), Olena Tsurkalenko (3), Michel Vaillant (6), Mesele Valenti (6), Liliana Vilas Boas (5), Maharshi Vyas (1), Richard Wade‐Martins (13), Evi Wollscheid‐Lengeling (1), Gelani Zelimkhanov (5). We thank Prof. Jochen Klucken for valuable feedback. (1) Luxembourg Centre for Systems Biomedicine, University of Luxembourg. (6) Luxembourg Institute of Health, Strassen, Luxembourg. (5) Centre Hospitalier de Luxembourg, Strassen. Luxembourg. (7) Laboratoire National de Santé, Dudelange, Luxembourg. (8) Centre Hospitalier Emile Mayrisch, Esch‐sur‐Alzette, Luxembourg. (9) Centre Hospitalier du Nord, Ettelbrück, Luxembourg. (10) Parkinson Luxembourg Association, Leudelange, Luxembourg. (11) Oxford Parkinson's Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. (12) Oxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK. (13) Oxford Centre for Human Brain Activity, Welcome Centre for Integrative Neuroimaging, Department of Psychiatry, University of Oxford, Oxford. (14) Centre of Neurology and Hertie Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, University Hospital of Tübingen, Tübingen, Germany. (15) Paracelsus‐Elena Klinik, Kassel, Germany. (16) Ruhr University of Bochum, Bochum, Germany. (17) Westpfalz‐ Klinikum GmbH, Kaiserlautern, Germany. (18) Department of Neurology, University Medical Centre Schleswig‐Holstein, Kiel, Germany. (19) Department of Neurology Philipps, University of Marburg, Marburg, Germany. (20) Association of Physiotherapists in Parkinson's Disease Europe, Esch‐sur‐Alzette, Luxembourg. (21) Private Practice Ettelbruck, Luxembourg. (22) Private Practice, Luxembourg, Luxembourg.

PY - 2022/11

Y1 - 2022/11

UR - https://www.scopus.com/pages/publications/85138753714

UR - https://pubmed.ncbi.nlm.nih.gov/36148927

U2 - 10.1002/mds.29212

DO - 10.1002/mds.29212

M3 - Letter

C2 - 36148927

AN - SCOPUS:85138753714

SN - 0885-3185

VL - 37

SP - 2315

EP - 2317

JO - Movement Disorders

JF - Movement Disorders

IS - 11

ER -

Disease Progression, Resilience, and Inflammation Markers During the Coronavirus Disease 2019 Pandemic in Parkinson's Disease

Access to Document

Other files and links

Cite this